Ma Ding

[Expert Profile] Ma Ding, Chief Physician, Professor, Doctoral Supervisor, is an authoritative expert in gynecologic oncology in China, working in the Department of Obstetrics and Gynecology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology. He has long been dedicated to clinical diagnosis, treatment, and scientific research of relapsed/refractory ovarian cancer and difficult gynecologic malignancy cases, and is an important leading figure in obstetrics and gynecology and gynecologic oncology in China.

[Education & Career] Professor Ma Ding graduated from Tongji Medical University, completed systematic clinical training at Tongji Hospital, and further studied at famous international gynecologic oncology centers. He has long served as Director of the Department of Obstetrics and Gynecology at Tongji Hospital, holding important academic positions including Chair of the Gynecologic Oncology Branch of the Chinese Medical Association. He has presided over projects including the National Key R&D Program and key grants from the National Natural Science Foundation of China, and is an academic leader in the field of gynecologic oncology in China.

[Areas of Expertise] Professor Ma specializes in comprehensive treatment of relapsed/refractory ovarian cancer, standardized surgery and chemoradiotherapy for gynecologic malignancies such as cervical cancer and endometrial cancer, as well as multidisciplinary comprehensive management of difficult gynecologic malignancy cases. He has profound expertise in precise staging of gynecologic tumors, tumor cytoreductive surgery and hyperthermic intraperitoneal chemotherapy, maintenance therapy, and targeted immunotherapy. He excels at managing refractory ovarian cancer patients with "recurrence and metastasis and failure of multiple lines of treatment," helping numerous patients prolong survival and improve quality of life.

[Academic Achievements & Industry Contributions] Professor Ma has led the establishment of a gynecologic oncology clinical research and translational research platform, systematically conducting research on early diagnostic biomarkers and drug resistance mechanisms in ovarian cancer, and leading the completion of multiple multi-center clinical studies, with findings published in top international journals. He has led the development of Chinese gynecologic oncology diagnosis and treatment guidelines and expert consensus statements, actively promoted standardized diagnosis and treatment of gynecologic malignancies, MDT models, and early screening and diagnosis system construction, and organized nationwide gynecologic oncology specialty training, making outstanding contributions to gynecologic oncology prevention and treatment in China.

[Clinical Practice & Outstanding Contributions] For decades on the front lines of obstetrics and gynecology and gynecologic oncology clinical work, Professor Ma has treated tens of thousands of patients with various gynecologic tumors, successfully managing numerous advanced and recurrent gynecologic malignancy patients. He has received multiple national awards including the National Science and Technology Progress Award, trained a large number of gynecologic oncology leaders, and is deeply trusted by patients and respected by peers alike. He is a truly deserving authoritative expert in the field of gynecologic oncology in China.

[Honors & Reputation] Professor Ma Ding serves as Director of the Department of Obstetrics and Gynecology at Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology and Chair of the Gynecologic Oncology Branch of the Chinese Medical Association, among other academic positions. He has presided over national-level projects including the National Key R&D Program and key grants from the National Natural Science Foundation of China, and is an authoritative expert in the fields of obstetrics and gynecology and gynecologic oncology in China. He has profound expertise in the diagnosis and treatment of relapsed/refractory ovarian cancer and difficult gynecologic malignancy cases. He has led the establishment of a gynecologic oncology clinical research and translational research platform, systematically conducting research on early diagnosis and drug resistance mechanisms in ovarian cancer, with findings published in top international journals and receiving the National Science and Technology Progress Award. He has trained a large number of gynecologic oncology leaders, and is deeply trusted by patients and respected by peers alike.